Intercept Pharmaceuticals (ICPT) Outlook Unchanged Following Earnings - Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Intercept Pharmaceuticals (ICPT) Outlook Unchanged Following Earnings - Baird
November 10, 2015 11:05 AM EST
Intercept Pharma (NASDAQ: ICPT) hit session highs Tuesday morning, rising 12%.
...
More
November 10, 2015 9:39 AM EST
Intercept Pharmaceuticals (NASDAQ: ICPT) reported Q3 EPS of ($2.10) vs consensus of ($2.74). As of September 30, 2015, ICPT had cash of $695.7M and cash burn was $36.5M. The net loss increase was primarily the result of increases in G&A expenses related to ICPT's corporate and pre-commercial activities.
Intercept projects adjusted operating expenses for the year ending December 31, 2015 will be below its... More
November 9, 2015 2:21 PM EST
Needham & Company analyst Alan Carr reiterating a Buy rating and $500 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following earnings and the company's corporate update today.
Carr commented, "Intercept mgmt provided a 3Q15 corporate update this morning. Key upcoming milestones include the Obeticholic... More
November 9, 2015 9:14 AM EST
Intercept Pharma (NASDAQ: ICPT) reported Q3 EPS of ($2.10), $0.65 better than the analyst estimate of ($2.75). Revenue for the quarter came in at $445 thousand versus the consensus estimate of $420 thousand.
As of September 30, 2015, Intercept had cash, cash equivalents and investment securities available for sale of approximately... More
